Cover Story
By Matthew Bin Han Ong
A federal judge has ruled against the Health Resources and Services Administration over provider access to 340B Drug Pricing Program discounts for orphan drugs.
By Matthew Bin Han Ong
In Brief
Funding Opportunities
Drugs & Targets
Trending Stories
- GRAIL’s woes raise questions about the prospects of MCDs and standards for their evaluation
- Mount Sinai oncologist Krystal Cascetta, 40, and her infant daughter die in Somers, NY, home
- How the 2024 elections can impact cancer policy
- University of Hawai‘i Cancer Center receives NCI designation with “outstanding” score
- NCI’s myeloMATCH will use biomarkers to match patients with myeloid cancer to trials
- New exhibit: Presidential elections and tobacco